Antifungal activity of the repurposed drug disulfiram against .

Journal: Frontiers in pharmacology
Published Date:

Abstract

Fungal infections have become clinically challenging owing to the emergence of drug resistance in invasive fungi and the rapid increase in the number of novel pathogens. The development of drug resistance further restricts the use of antifungal agents. Therefore, there is an urgent need to identify alternative treatments for (). Disulfiram (DSF) has a good human safety profile and promising applications as an antiviral, antifungal, antiparasitic, and anticancer agent. However, the effect of DSF on Cryptococcus is yet to be thoroughly investigated. This study investigated the antifungal effects and the mechanism of action of DSF against to provide a new theoretical foundation for the treatment of infections. studies demonstrated that DSF inhibited growth at minimum inhibitory concentrations (MICs) ranging from 1.0 to 8.0 μg/mL. Combined antifungal effects have been observed for DSF with 5-fluorocytosine, amphotericin B, terbinafine, or ketoconazole. DSF exerts significant protective effects and synergistic effects combined with 5-FU for infected with . Mechanistic investigations showed that DSF dose-dependently inhibited melanin, urease, acetaldehyde dehydrogenase, capsule and biofilm viability of . Further studies indicated that DSF affected by interfering with multiple biological pathways, including replication, metabolism, membrane transport, and biological enzyme activity. Potentially essential targets of these pathways include acetaldehyde dehydrogenase, catalase, ATP-binding cassette transporter (ABC transporter), and iron-sulfur cluster transporter. These findings provide novel insights into the application of DSF and contribute to the understanding of its mechanisms of action in .

Authors

  • Min Peng
    Department of Dermatology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
  • Chen Zhang
    Department of Dermatology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
  • Yuan-Yuan Duan
    Affiliated Hospital for Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China.
  • Hai-Bo Liu
    Department of Dermatology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
  • Xin-Yuan Peng
    Department of Dermatology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
  • Qian Wei
    Department of Dermatology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
  • Qi-Ying Chen
    Department of Dermatology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
  • Hong Sang
    Department of Dermatology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
  • Qing-Tao Kong
    Department of Dermatology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.

Keywords

No keywords available for this article.